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Abstract
Background: Lacking suitable alternatives, the control of malaria increasingly depends upon Artemisinin Combination
Treatments (ACT): resistance to these drugs would therefore be disastrous. For ACTs, the biology of resistance to the
individual components has been investigated, but experimentally induced resistance to component drugs in combination
has not been generated.
Methodology/Principal Findings: We have used the rodent malaria parasite Plasmodium chabaudi to select in vivo
resistance to the artesunate (ATN) + mefloquine (MF) version of ACT, through prolonged exposure of parasites to both
drugs over many generations. The selection procedure was carried out over twenty-seven consecutive sub-inoculations
under increasing ATN + MF doses, after which a genetically stable resistant parasite, AS-ATNMF1, was cloned. AS-ATNMF1
showed increased resistance to ATN + MF treatment and to artesunate or mefloquine administered separately. Investigation
of candidate genes revealed an mdr1 duplication in the resistant parasites and increased levels of mdr1 transcripts and
protein. There were no point mutations in the atpase6 or ubp1genes.
Conclusion: Resistance to ACTs may evolve even when the two drugs within the combination are taken simultaneously and
amplification of the mdr1 gene may contribute to this phenotype. However, we propose that other gene(s), as yet
unidentified, are likely to be involved.
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Introduction
Anti-malarial drug resistance poses a serious challenge for the
effective control of malaria. Plasmodium falciparum, the causative
agent of the most severe form of the disease to humans, has
evolved extensive resistance to almost all known drugs, except for
Artemisinin (ART) derivatives [1]. ART derivatives are currently
used in combination with a chemically unrelated drug in most
malaria endemic countries with the purpose of reducing the
probability of drug resistance evolution [2] and possibly of
augmenting therapeutic efficacies by exploiting synergistic effects
of their component drugs.
The ability of Artemisinin Combination Therapy (ACT) to
delay resistance evolution may depend upon whether the two
drugs share the same resistance mechanisms and whether there is
pre-existing resistance to one or other of the drug components.
Additionally, the possibility of resistance increases if incomplete
treatment is received by the patient (counterfeit drugs, non-
compliance, mal-absorption, vomiting, etc) [3] or if under
inadequate supervision, ACT components are used alone or at
sub-optimal concentrations or intervals [4]. These scenarios allow
parasites to be exposed to sub-therapeutic levels of the drug, thus
contributing to the selection of tolerant strains that would later
give rise to resistance.
Regions of low endemicity have historically been the cradle of
newly emergent resistant parasites. For example, mefloquine- (MF)
resistant P. falciparum parasites arose in South-East Asia after ten years
of MF monotherapy [5]. In order to face increasing levels of MF
resistance, the ACT version of artesunate-mefloquine (ATN + MF)
was introduced in SE Asia in 1994, restoring the favourable clinical
outcome with cure rates reaching as high as 100% [6]. However,
recent reports of increased in vitro IC50 and reduced parasite clearance
rates have raised the prospect that the efficacy of the ATN component
may be fading [7–9]. Consequently, an understanding of the biology
and genetics of ACT resistance will provide evidence-based
information to monitor, delay or prevent the evolution of resistance.
The genetics of resistance to individual components of ACT in
P. falciparum has been well-studied, but is still incompletely
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understood. For ART, its anti-malarial effect has been proposed to
be mediated by its inhibition of the SERCA type Ca2+-pump,
ATPase6, [10–11]. Mutations in the atpase6 gene were associated
with increases in artemether in vitro IC50 in South America [12],
but direct experimental evidence for atpase6 involvement has yet to
be presented. Also, in two recent independent reports, the atpase6
gene was not mutated in parasites confirmed to have markedly
reduced in vivo susceptibility to artesunate in Western Cambodia
[7–8].
The role of pfmdr1 has also been extensively investigated. It
encodes a P-glycoprotein whose over-expression is responsible for
multi-drug resistance in cancer cells [13]. In P. falciparum, field
studies [14–19], drug selection experiments [20–21], genetic
manipulation [22], and the identification of selective sweeps
around the mdr1 locus [23–24], have provided evidence to support
the role of pfmdr1 gene amplification in resistance to MF and
lumefantrine as well as to the chemically unrelated ART
derivatives. However, as with atpase6, no association was found
between mdr1 genotypes and the first confirmed cases of reduced in
vivo susceptibility to ATN [7–8].
The AS lineage of multidrug-resistant mutants of Plasmodium
chabaudi (Figure 1) has been developed by experimental evolution
and is a useful model to investigate questions regarding the in vivo
biology of antimalarial resistance [25]. Because all parasites within
this lineage are isogenic, direct comparisons between resistant
mutants and their sensitive progenitors offers a simple and
informative means of identifying mutations conferring resistance.
P. chabaudi parasites show similar mechanisms for resistance to
pyrimethamine and MF: mutations in dhfr [26] (in AS-PYR) and
amplification of mdr1 [27] (in AS-15MF), respectively (Figure 1).
Genetic and candidate gene analysis of an artemisinin-resistant
strain of P. chabaudi [28] identified the locus (chromosome 2)
conferring in vivo ART resistance and revealed two point mutations
in a gene (ubp1) encoding a de-ubiquitinating enzyme [29].
Interestingly, a UBP-1 V2728F mutation was detected in the MF-
resistant parasites AS-15MF, which had never been exposed to
ART in their selection history (unpublished data).
Although the biology and genetics of drug resistance to each
component drug of ACT has been studied separately, less is known
about the factors influencing ACT resistance and its acquisition, as
a whole. For instance, assuming that two independent mutations
are required to confer resistance to the two component drugs, it is
not known whether the mutation rate in Plasmodium spp. can
produce the two mutations in one parasite (in one host) at a
sufficient frequency, or whether these mutations confer fitness
advantages if the two component drugs are administered at the
same time.
In order to address the above issues, we have used Plasmodium
chabaudi to investigate the evolution of resistance to ACTs, by
selecting in vivo resistance to ATN + MF through prolonged
exposure to both drugs simultaneously. Resistant parasites were
successfully generated, and their atpase6, ubp-1 and mdr1 genes
were compared to those of the sensitive progenitor.
Results
Selection and cloning of artesunate + mefloquine-
resistant parasites
AS-ATN (Fig. 1), a parasite clone previously selected for limited
artesunate (ATN) resistance [28], was used as the starting
biological sample and subjected to prolonged and increasing
exposure to the two drugs over many generations.
The AS-ATN parasite was first inoculated into a group of mice
which received a sub-curative drug dose consisting of 5 mg/kg of
ATN +1 mg/kg of mefloquine (MF), given over a 3-day course
(Figure 2). After approximately seven days, parasites which
survived this treatment were sub-inoculated into uninfected mice
and treated with a slightly higher dose. This procedure was
Figure 1. Drug resistance lineage of Plasmodium chabaudi AS. Note: the Figure does not depict all drug-resistant clones within the AS lineage.
Only those relevant to the present work are represented. Each drug used to select resistant clones is noted inside each arrow and the increasing
colour tonality of the arrow represents an approximation of the increase in drug doses during the evolution of resistance. The length of each arrow
depicts the approximate relative time for generating the resistance phenotype. The generation of pyrimethamine resistance was a result of a single-
step selection, whilst for all other drugs the evolution of resistance resulted from prolonged exposures to small increments in drug concentrations
over many generations. The genotypic differences between a particular parasite and its progenitor are noted in brackets. Asterisks depict the clones
used in this work.
doi:10.1371/journal.pone.0011593.g001
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repeated using drug doses which were adjusted at each stage,
depending on the extent of parasite recovery during the previous
treatment (Figure 2). After twenty-seven of such passages, the
drug-selected parasites were shown to tolerate 30 mg/kg/day
ATN +3.5 mg/kg/day MF. This line is likely to contain parasites
with different genotypes and phenotypes. Therefore, they were
subjected to a cloning process in order to isolate and propagate a
genetically homogeneous ATN + MF-resistant parasite. Five
clones were obtained from a group of 20 mice each receiving a
calculated inoculum of 0.5 parasites/mouse in (Figure 2) and eight
clones from a group of 20 mice injected with a mean of 1 parasite/
mouse (data not shown). The fastest growing clone within the first
group, termed herein AS-ATNMF1 (Figure 2), was chosen for
subsequent phenotypic and genotypic evaluation.
Evaluation of ATN + MF resistance in drug tests
The AS-ATNMF1 clone described above was submitted to
drug-treatment in parallel with parasites of the AS lineage which
had never been exposed to ATN + MF. These controls comprised
AS-3CQ (sensitive to both ATN and MF), the MF-resistant
parasite AS-15MF, and the AS-ATN progenitor. ATN + MF
responses were thus evaluated under 40 mg/kg/day ATN +4 mg/
kg/day MF administered for 3 days in groups of five mice along
with untreated controls. The above doses were slightly higher than
those used at the end of the selection procedure because parasites
were growing well under 30 mg/kg/day ATN +3.5 mg/kg/day
MF (data not shown).
In the absence of treatment, all four parasite clones grew well in
mice, as expected, with peak parasitaemias reaching between circa
40% (AS-ATN) and 80% (AS-ATNMF-1) between days 5 and 6
post-inoculum (p.i.) (Figure 3A). Under ATN + MF treatment, no
parasites were detected in mice infected with either AS-3CQ or
AS-15MF over a 15-day p.i. follow-up, whilst AS-ATN showed a
slight (,5%) recrudescent parasitaemia (days 12–15) (Figure 3B).
Thus, AS-3CQ, AS-15MF and AS-ATN were deemed as sensitive
to ATN + MF combination treatment. In contrast, mice infected
with the drug-selected clone AS-ATNMF1 failed to clear
parasitaemias after drug-treatment, with parasites being first
detected on day 8 p.i. and peak parasitaemias of circa 30%
occurring on day 11 p.i (Figure 3B).
We conclude that an ATN + MF-resistant parasite was
successfully selected and cloned. The resistance phenotype was
stable after successive freeze-thaw cycles (data not shown).
Evaluation of response to individual drugs (ATN and MF)
In order to investigate whether the evolution of resistance to
ATN + MF treatment also increased the resistance to the
individual components of the ACT, we evaluated the individual
ATN and MF responses of AS-3CQ, AS-ATN, AS-15MF and AS-
ATNMF1. Drug doses used in these tests were higher for
individual drugs than those used in the combination treatments
because individual components are generally less effective when
used as monotherapy.
In both ATN and MF tests, all untreated control parasites grew
as expected, with parasitaemias reappearing in infected mice on
day 4 p.i. and reaching peak values one to two days later
(Figure 3A).
The MF-resistant phenotype of AS-ATNMF1 was very marked
in comparison to the remaining clones (Figure 3C). Thus, under a
daily dose of 8 mg/kg/day, AS-ATNMF1 parasites recrudesced
on day 4 p.i. and reached a high peak parasitaemia of 46% on day
9 p.i. In contrast, AS-3CQ was classified as MF-sensitive, because
parasites were not detectable throughout the course of the
experiment (Figure 3C). Interestingly, AS-15MF was previously
defined as MF resistant at 6 mg/kg/day [27] but here it is sensitive
to 8 mg/kg/day (Figure 3C). Finally AS-ATN showed a small
peak parasitaemia which was delayed until at least day 15 p.i
(Figure 3C). Therefore, AS-ATNMF1 has increased MF resistance
relative to its progenitors and to the independently selected MF-
resistant clone AS-15MF.
Figure 2. In vivo evolution of resistance to artesunate + mefloquine. Artesunate (ATN) and mefloquine (MF) were given together to P.
chabaudi-infected mice over many generations. After twenty seven sub-inoculations under increasing ATN + MF exposure, the drug-resistant
population was cloned. One of these clones, denoted AS-ATNMF1, was selected from subsequent studies.
doi:10.1371/journal.pone.0011593.g002
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In the ATN response test, a dose of 80 mg/kg/day (3 day
treatment) was used. For the ATN- and MF-sensitive parasite AS-
3CQ, recrudescence was first observed on day 13 p.i., with peak
parasitaemias reaching 9% on day 14 (Figure 3D). In contrast, AS-
ATNMF1 parasites appeared on day 5 p.i. and reached 28% on
day 9 p.i (Figure 3D). The MF-resistant parasite, AS-15MF, also
displayed some resistance to ATN, first producing observable
parasites on day 4 p.i. and peak parasitaemias of 24% on day 8 p.i
(Figure 3D). The parasitaemia cleared rapidly. ATN-resistant AS-
ATN parasites showed an intermediate phenotypes, producing
parasites on day 6 p.i peak parasitaemia of 28% on day 11 p.i
(Figure 3D). The ATN drug tests therefore show that AS-
ATNMF1 does have increased resistance to ATN relative to its
progenitor, AS-ATN.
AS-ATNMF1 therefore shows increased resistance to both MF
and ATN components individually, as well as to their combination
ATN + MF.
atpase6, ubp-1 and mdr1 genotypes in AS-ATNMF1
P. chabaudi AS-ATNMF1 parasites were interrogated for
mutations in candidate genes previously implicated in resistance
to each of the drugs employed here. Thus, we first searched for the
presence of point mutations in those genes proposed to be involved
in the increased tolerance to ART derivatives, namely atpase6
[10,12] and ubp1 [29]. To this purpose, the whole coding sequence
of both genes was sequenced and no differences were found
between AS-ATNMF1 and its progenitor AS-ATN.
Changes in the copy number of the pfmdr1 gene are frequently
found to be present in MF-resistant parasites [16,27] and have also
been reported to confer selective advantage in the presence of
ART drug pressure [16,30]. In this context, we investigated by real
time PCR whether the evolution of ATN + MF-resistance had
selected parasites with increased mdr1 copy number or mRNA
expression. Because both AS-ATN and AS-3CQ are known to
harbour a single copy of the mdr1 gene [28,31], and AS-15MF has
been shown previously to carry two copies [27], these clones were
also analysed. Real-time qPCR was thus carried out using a
TaqManH assay as detailed in the ‘‘Materials and Methods’’ and
data were expressed as the mean N-fold difference 6 SE in mdr1
gene copies of each of the above parasite clones in relation to
either AS-SENS or AS-ATN.
AS-ATNMF1 displayed 1.860.09 and 1.860.37 mdr1 copies
relative to the single-copy AS-ATN progenitor and AS-SENS,
respectively (Figure 4). Conversely, the estimated copy number
between AS-ATNMF1 and the two-mdr1 copy parasite AS-15MF
was approximately equal (Figure 4). These results provide strong
indication that AS-ATNMF1 carries two copies of the mdr1 gene,
one of which was gained in the course of the evolution of resistance
to the ATN + MF combination treatment.
In line with an increase in mdr1 copy number, mRNA levels
were also found to be increased in AS-ATNMF1, showing that the
genomic amplification is accompanied by increased transcription
(Figure 4). Thus, the fold-increase of AS-ATNMF1 mdr1 mRNA
transcripts was 2.660.17 and 3.460.22, relative to its single copy
number progenitor AS-ATN and to AS-3CQ, respectively.
Interestingly, relative mRNA levels in both AS-ATNMF1 and
AS-15MF are higher than those of gene copy number, as
determined by cDNA/genomic DNA ratios (Table 1).
MDR1 protein levels are increased in AS-ATNMF1
In order to determine whether the increase in genomic copies
and transcription of the mdr1 gene was accompanied by an
increase in its product, we measured the relative amount of MDR1
Figure 3. Drug test results. Each line represents the evolution of
parasitaemia in each parasite clone from day 4 post-inoculum (p.i) in
the absence of treatment (a), under artesunate + meloquine treatment
(b), under mefloquine treatment (c) or under artesunate treatment (d).
Each data point is a mean of % parasitaemias 6 SE resulting from reads
of groups of two and five mice in the untreated and treated groups,
respectively.
doi:10.1371/journal.pone.0011593.g003
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protein in the different parasite clones, using quantitative Western
blot analysis.
Because MDR1 levels have been shown to be expressed in
correlation with the gene copy number in previous studies [20,30],
we expected protein amounts to be approximately doubled in AS-
15MF and AS-ATNMF1, in line with the quantitative gDNA and
mRNA analysis. We observed a considerable increase in the
amount of MDR1 in both the MF-resistant parasites, AS-15MF
and in AS-ATNMF1 in relation to the mdr1 single copy parasites
AS-3CQ and AS-ATN (see Figure 5). Thus, AS-15MF displayed a
6.260.88 and 5.060.30 fold increase in MDR1 levels in
comparison to AS-3CQ and AS-ATN, respectively (Figure 4).
For AS-ATNMF1, the amount of MDR1 was augmented
5.660.44 fold when compared to AS-3CQ, and 4.560.80 fold
in relation to AS-ATN (Figure 4). There is thus a disproportionate
increase in the expression of MDR1 protein relative to gene copy
number in the resistant parasites (Table 1). These observations
suggest that the post-translational regulation of MDR1 may be
complex.
Finally, we compared MDR1 levels between the single mdr1
copy ATN-resistant parasites AS-ATN and AS-3CQ. Interesting-
ly, there was a small but significant increase of MDR1 protein in
AS-ATN [1.460.0.17 (p = 0.05)] relative to AS-3CQ (Figure 4).
Discussion
Here, we aimed to generate a parasite resistant to the artesunate
+ mefloquine (ATN + MF) version of ACT. For this, AS-ATN, a
parasite clone previously selected for limited artesunate (ATN)
resistance [28], was used as the starting biological sample and
subjected to prolonged and increasing exposure to the two drugs
over many generations. The reasons for using this parasite were
two-fold: firstly, the possibility that mdr1 would be amplified
following ATN + MF pressure could be investigated, because AS-
ATN harbours a single mdr1 copy. Secondly, since ATN-resistant
parasites have recently been reported from South-East Asia [7–9],
where the ATN + MF combination is widely deployed, the present
results may provide important early insights on the evolution of
ATN + MF resistance on an ATN-resistant background.
Two major key outcomes of this work deserve particular
consideration. First, by deriving an ATN + MF-resistant clone, we
have shown that resistance may evolve to two drugs and their
combination even when the two drugs are given simultaneously.
Consequently, the chance of selecting a resistant parasite
harbouring mutation(s) that enable it to withstand the effects of
both drugs within a combination may be higher than previously
perceived. That strategy is predicated on the principle that each of
the drugs should have different modes of action and thus elicit
distinct parasite response mechanisms [2]. There may be
evolutionary implications to these results. One is that because this
is an artificial in vivo model where drugs are given initially at low
doses and slowly increased over a number of generations in a
controlled environment, there is a higher chance of resistant
mutants surviving onto subsequent generations. Unfortunately,
however, non-optimal drug dosing is also often encountered in
natural parasite populations of P. falciparum because of different
factors, such as inadequate compliance to treatment [4], rapid
drug clearance in some patients [32] or the distribution of sub-
standard drug formulations that contain lower amounts of the
Table 1. Relationships between genomic DNA, transcript and
protein amounts of mdr1 between the different parasite
clones.
Expression ratios
AS-3CQ as control AS-3CQ AS-ATN AS-15MF AS-ATNMF1
cDNA/gDNA - 1.40 1.56 1.88
Protein/cDNA - 1.00 2.48 1.64
Protein/gDNA - 1.40 3.87 3.11
AS-ATN as control
cDNA/gDNA 0.70 - 1.4 1.44
Protein/cDNA 1.00 - 2.4 1.70
Protein/gDNA 1.00 - 3.33 2.50
Values were determined by dividing the mean N-fold expression between each
molecular species.
doi:10.1371/journal.pone.0011593.t001
Figure 5. Typical Western blot result depicting MDR1 expres-
sion in the artesunate + mefloquine resistant clone AS-
ATNMF1. Hybridization was carried out with a anti Pgh1 antibodies
and a anti tubulin antibodies. AS-3CQ and AS-ATN were used as one-
mdr1 copy controls and AS-15MF was used as the two-mdr1 copies
control.
doi:10.1371/journal.pone.0011593.g005
Figure 4. Differences in mdr1 genomic DNA, cDNA and protein
amounts between the different parasite clones. Columns
represent mean of five independent experiments with corresponding
Standard Error bars. Cases were differences in relative mdr1 amounts
between a particular parasite and its one copy comparator (AS-3CQ or
AS-ATN) are statistically significant after Student’s t-tests are represent-
ed by * (p#0.01) or ** (0.05$p$0.01).
doi:10.1371/journal.pone.0011593.g004
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active compounds [33]. Therefore, a similar scenario to that
modelled here may also occur in human malaria, promoting
selection of ACT-resistant mutants in a similar fashion.
It is also possible that the rate of occurrence of multiple
mutations conferring resistance to the drug combination is higher
than expected and/or that both drugs actually share common
mechanisms of resistance. We note that the sensitive progenitor
parasite AS-ATN used here already has a lower level of resistance
to ATN and carried a pre-existing mutation in the ubp-1 gene [29]
which may have facilitated further evolution of resistance.
However, because P. falciparum parasites with a markedly reduced
susceptibility to ATN have recently been reported from South-
East Asia [7–9], the ATN-resistant background used here may
help us to gain insights into the further evolution of resistance to
ATN + MF in that field situation.
The second important consequence of the present work is that it
demonstrates the selection of parasites harbouring two copies of
the mdr1 gene by in vivo ACT treatment. This was the only genetic
alteration detected following inspection of ubp1, atpase6 and mdr1
itself, the major candidate genes previously reported to be
associated to resistance to the drugs used here. Interestingly, the
pre-existing V2697F mutation in the ubp-1 gene was retained
following drug selection and no further mutations arose in this
gene. Is it possible that the ubp-1 mutation is acting in concert with
the mdr1 duplication in determining the ATN + MF resistance
phenotype by, for instance, reducing ubiquitination of MDR1 and
either allowing its increased turnover or modifying its localisation
within the parasite? If so, we might have expected that the
mefloquine (MF)-resistant clone AS-15MF would also be resistant
to the ATN + MF combination because it too bears a mutation in
ubp-1 as well as a duplication of the mdr1 gene. However, whilst
this genotype is sufficient to render it resistant to both MF (at a
lower level than AS-ATNMF1) and ATN when these drugs are
given separately, our data shows that it is not resistant to both
drugs simultaneously. In any case, AS-ATN also carries an ubp-1
mutation and is also fully sensitive to ATN + MF. The acquisition
of an extra mdr1 copy in AS-ATN is accompanied by the
acquisition of resistance to ATN + MF. In summary, whilst AS-
15MF and AS-ATNMF1 share both a mutation in ubp-1 and two
mdr1 copies, only the latter is resistant to the ATN + MF
combination. Therefore, these data appear to indicate that whilst
both genes may be involved in resistance to these drugs, the ATN
+ MF resistance phenotype is more complex and is likely to involve
mutation(s) in other gene(s). Further genomic, genetic and
functional analyses will be required to establish whether other
mutations are involved in ATN + MF resistance in AS-ATNMF1.
Although it is uncertain whether selection of the mdr1
duplication and its consequent overexpression was driven by
ATN, MF, or both, this result is similar to a number previous
studies suggesting a role for this gene in resistance to aminoqui-
nolines and artemisinin derivatives [19,21,22,24,30,34]. However,
we suggest that repeated MF treatment alone might select
parasites with mdr1 duplications and that these parasites would
show (as in this study) increases in MF-resistance, resistance to the
combination and, perhaps, slight increases in ATN resistance. The
present work is therefore providing further support for the
participation of mdr1 in a true multi-drug-resistant phenotype for
artemisinins and their partner drugs. Additionally, it is suggested
here that even under the putative scenario of MF being the major
selection pressure for mdr1 amplification, the presence of an ART
partner drug is not antagonistic to this process. As a matter of fact,
the opposite is more likely to occur as suggested here, and also
supported by previous data where disruption of one of two mdr1
copies in P. falciparum FCB has shown to result in a two-fold
increase in ART susceptibility [22]. Collectively, these observa-
tions have major public health consequences, as a shared drug
defence mechanism will undermine the efficacy of Artemisinin
Combination Therapies (ACTs) as a whole, and facilitate the
evolution of resistance.
Interestingly, the mdr1 and MDR1 expression data suggest that
changes in mdr1 copy number may be accompanied by larger
changes in the expression of both mRNA and protein. This
difference was observed exclusively in the clones that harboured
pre-existing ubp-1 mutations (AS-ATN, AS-15MF and AS-
ATNMF1), but not in AS-3CQ which carries a wild-type allele.
This unexpected result contradicts a simple model of post-
transcriptional or post-translational regulation of MDR1 and
was not observed previously in P. falciparum parasites selected in
vitro for MF and ART resistance [20,30]. One possible explanation
could be that ubp1 regulates MDR1 ubiquitination. Either the
26 S proteasome-dependent turn-over of MDR1 is modified from
one cellular location preferentially, or the distribution or
trafficking of MDR1 within the cell is modified. Either of these
outcomes could perturb the overall regulation of mdr1 mRNA and
protein expression. Although this hypothesis is preliminary and
highly speculative, the stability and steady-state expression of the
human homologue Pgp-1, has been shown to be amenable to
ubiquitin-dependent regulation in drug-resistant cancer cells [35],
providing an experimental precedent for the present observations.
In the absence of fully effective antimalarial treatments, the
evolution of resistance to ACTs would represent a major
shortcoming in worldwide efforts to control Plasmodium falciparum
malaria. Unfortunately, recent global concerns about the future
efficacy of ACTs have been triggered by the first indications that
artemisinin’s efficacy may be waning [7–9]. Because we lack new
effective drugs and effective treatments, there is a pressing
requirement to understand how the efficacy of present ACT
treatments may be protected. The results reported here may
contribute to improved understanding of the biology, dynamics
and genetic traits governing ACT resistance, which will provide
evidence-based information for improved drug surveillance and
future choice of the ACT combination components.
Materials and Methods
Ethics Statement
All animal work was conducted according to relevant national
and international guidelines after approval by the Ethics
Committee of the Instituto de Higiene e Medicina Tropical of
Lisbon, Portugal, under PARECER 2/2006 from August 1st 2006.
Parasites, hosts and strategy for selecting ACT-resistant
parasites
Cloned parasite lines from the isogenic AS lineage of the rodent
malaria parasite Plasmodium chabaudi were used in this work. Each
of these had been previously characterized for its response to the
drugs under study (Figure 1) and their genotype had been assessed
for each of the three candidate genes atpase6, ubp-1 and mdr1
(Figure 1). Our objective was to generate resistance to the
artesunate (ATN) + mefloquine (MF) version of ACT. The strategy
to achieve resistant parasites was based on the prolonged exposure
of parasites to consecutive small increments in drug doses in
treated mice over many generations. To achieve this goal,
parasites resistant to a low level of ATN (P. chabaudi AS-ATN)
were exposed to a combination of ATN and MF. Thus, blood
containing the parental clone AS-ATN was thawed and inoculated
intraperitoneally into two CD-1 6–8 week-old mice. When these
mice reached peak parasitaemia, donor blood was extracted to
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inoculate 10exp7 parasitized red blood cells (pRBC), diluted in
citrate saline, into two groups of two mice each. One group was
left untreated and parasites were sub-inoculated every seven days
into two uninfected mice in the absence of treatment and in
parallel with the treated group. The remaining two mice were
treated with a combination of ATN and MF dissolved on DMSO
on days 3, 4 and 5 post-inoculum (p.i.) by gavage. Infection
progression in individual mice was monitored from day 3 onwards
by counting the percentage parasitaemia in Giemsa-stained thin
blood smears. The treated mouse containing the highest
parasitaemia on day 7 p.i., was then exsanguinated by section of
the brachial artery under general anesthesia and served as donor
for the next round of drug selection. The starting drug-selecting
dose was of 1 mg/Kg/day of MF administered together with
5 mg/kg/day of ATN and it was increased whenever parasitae-
mias reached above 2% on day 7, under drug treatment. After 27
rounds of drug selection, parasites under drug pressure were
cloned by limiting dilution [36]. The parasite population surviving
treatment was cloned by limiting dilution at the end of this period.
ATN was kindly donated by Dafra Pharma InternationalTM.
Mefloquine was purchased from RocheTM. Drugs were freshly
diluted into DMSO (MerckTM) prior to administration.
Drug sensitivity test
In order to assess the success of drug resistance evolution,
parasites were tested for their drug responses, at the end of the
drug selection period, as follows. In these tests, 4–6 week-old
inbred Balb/c mice were used. For each drug to be tested
(artesunate, mefloquine or artesunate + mefloquine) mice were
divided into four groups of 10 mice and each mouse within the
group was inoculated with 10exp7 pRBC with one of the following
parasite clones (Figure 1): i) the drug-selected clone AS-ANTMF1,
ii) its sensitive progenitor AS-ATN, resistant to low levels of ATN),
iii) a MF resistant clone denoted AS-15MF, and iv) AS-3CQ,
which is resistant to low doses of chloroquine, but sensitive to both
MF and ATN. Each group was further divided into two sub-
groups, one of which was given the diluting vehicle DMSO and
the other was treated with the drug being assayed. Treatment
regimes consisted of a daily dose first administered on day one p.i.
for three consecutive days. Individual percentage (%) parasitae-
mias were then followed from day 4 onwards and up to day 15 and
results were expressed as daily average % parasitaemias from the
five mice within each experimental group. In order to obviate
suffering, mice were sacrificed through cervical dislocation
whenever they reached peak parasitaemias.
PCR and sequencing
Blood from mice bearing each of the parasites mentioned above
was dried in Whatman nu4 filter paper for DNA extraction. 1 cm2
of the filter paper was incubated overnight in 1 ml PBS (Sigma)
+0.5% saponin (Sigma) at 4uC. The solution was removed and the
filter paper was incubated with 1 ml PBS at 4uC for 30 minutes.
After the removal of PBS, the filter paper was incubated at 100uC
with pre-heated 200 ml PBS +5% Chelex-100 (BioRadTM) for 10
minutes and vortexed vigorously every 5 minutes. The tubes were
centrifuged at 14000 rpm for 2 minutes and the supernatant was
placed into a fresh tube. The supernatant (containing the DNA)
was centrifuged again in order to insure the complete removal of
the Chelex-100 matrix and stored at 220uC.
The sequences of the P.faciparum ortholog genes pcatpase6
(PCAS_020540) and pcubp-1 (PCAS_020720) were obtained from
plasmoDB and used for comparing the fragments obtained when
analysing DNA from the parasites selected here with their
progenitors. The primer sequences as well as the cycling
conditions for the pcatpase6 gene were described previously by
Afonso et al, 2006 [28] whereas the primer sequences and cycling
conditions for the gene pcubp1 were described previously by Hunt
et al, 2007. The only exception are the primers surrounding the
V2697F mutation, characteristic of the AS-ATN clone [29]. The
forward sequence is 59-GTTACCAATTGATACGACTG-39 and
the reverse sequence is 59CAGAATTAGTATGAGGTGGC-39.
1 ml of DNA from each sample was used as template in 50 ml
reactions. The other reagents were added to a final concentration
of 1,5 mM MgCl2, 0.2 mM dNTP (each), 0.2 pmol/ml forward
and reverse primers, and 1.25 U of Go Taq Flexi DNA
Polymerase (Promega). The cycling conditions were: denaturation
at 94uC for 39, 15 cycles of 94uC for 1599, 40uC for 4599 and 68uC
for 49, followed by 30 cycles of 94uC for 19, 45uC for 4599 and
72uC for 39. The final elongation was run for 109 at 72uC.
PCR products were sequenced by de-deoxy sequencing and
sequences were aligned using Multi-Align [37], a multiple
sequence alignment software available online (http://bioinfo.
genotoul.fr/multalin/multalin.html).
Assessement of pcmdr1 copy number and mRNA
expression by quantitative Real-time PCR
DNA samples above were used to determine the copy number of
the pcmdr1 (PCAS_123820) in ATN + MF-resistant clones, using a
TaqManTM probe assay. Quantification was made based on relative
estimates of genomic target DNA amounts between different parasite
clones, using the 22DDct method [38], and data was normalized
against the house keeping gene pc-atubulin ( PCAS_052240). Parasite
clones of known mdr1 copy number, AS-SENS, AS-ATN and AS-
15MF, were used as controls, the two former harbouring one copy
and the latter, two copies of mdr1 [27–28].
Oligonucleotide primers and TaqManTM probes (Table 2) were
obtained through the services of TIBMOLBIOL and designed
such as PCR reactions for both genes could be ran in the same
plate (using the same cycling conditions). DNA samples, primers
and probes were added to Faststart Universal Probe Master Mix
with ROX (RocheTM), according to the manufacturer’s instruc-
tions and submitted to 95uC for 10 minutes followed by 50 cycles
of denaturation at 95uC for 15 seconds and annealing/extension at
57uC for 1 minute.
In order to evaluate relative differences in mdr1 expression at the
mRNA level, the same procedure as that described above was
applied to template cDNA of each of the parasite clones. For this,
RNA was first extracted from blood stage parasites in order serve as
template for cDNA synthesis as follows. Parasite-infected mice were
bled out and the mixture of blood and Citrate Saline Solution was
filtered in a cellulose (CF11, Sigma) 5 ml column. This was then
centrifuged at 3000 rpm for 5 minutes at room temperature and the
supernatant was discarded. The volume of the erythrocyte pellet
was estimated and an equal volume of Citrate Saline Solution was
added to it and mixed gently. RNA from this pellet was then
extracted using RNA Blood Kit 100 (BioRadTM) following the
manufacturer’s instructions with minor changes described bellow.
Briefly, 300 ml of blood was mixed by inversion with 900 ml of RBC
Lysis Solution, provided with the kit. The mixture was incubated at
room temperature for 10 minutes and then centrifuged at
14000 rpm for 10 minutes at 4uC. The supernatant was discarded
leaving approximately 20 ml of residual liquid that was thoroughly
mixed with the pellet. Subsequently, 300 ml of RNA Lysis Solution
was added and mixed by pipetting repeatedly. 100 ml of the Protein-
DNA Precipitation Solution was added and the mixture was
incubated on ice for 10 minutes. The samples were centrifuged at
14000 rpm for 5 minutes at 4uC and the pellet was discarded.
300 ml of 100% Isopropanol was added to the supernatant and
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centrifuged at 14000 rpm for 5 minutes at 4uC. The supernatant
was poured out and the tube was briefly dried using an absorbent
paper. The pellet was washed in 70% Ethanol. After being
centrifuged again under the same conditions as above, the
supernatant was rejected and the tube was allowed to air-dry for
15 minutes. 50 ml of RNA Hydration Solution was added to the dry
pellet and the tube was kept on ice for 30 minutes.
The RNA sample obtained as described above was either used
immediately for cDNA synthesis or kept at -70uC. Before starting
cDNA synthesis, samples were treated with DNAse to ensure the
removal of any contaminant DNA. Thus, 4 ml of the RNA sample
was mixed with 1.0 ml of 106DNAse Buffer (FERMENTASTM),
1.0 ml of 1 U/ml DNAse (FERMENTASTM) and 5.0 ml of DEPC
treated water and incubated for 15 minutes at room temperature.
1.0 ml of 25 mM EDTA was added to the reaction mixture and
incubated at 65uC for 5 minutes. Reverse transcription of the
DNAse treated RNA began by the addition of 2 ml of 106
concentrated Hexanucleotide Mix (RocheTM). The tube was
placed in a dry bath at 70uC for 5 minutes and later cooled on ice.
After that, a mixture consisting of 4 ml of 106 M-Mulv Buffer
(FERMENTASTM), 2 ml of deoxynucleoside triphosphate mix
(10 mM each), 3 ml of 100 mM DTT, 0.5 ml of 400 U/ml RNA
inhibitor RibolockTM (FERMENTASTM), and 7.5 ml of DEPC
treated water was prepared. 17 ml was added to the mixture of
DNAse treated RNA and Hexanucleotides and it was incubated at
25uC for 5 minutes. 1 ml of 200 U/ml M-MuLV Reverse
Transcriptase (FERMENTASTM) was added and the reverse
transcription was performed by one cycle of 25uC for 10 minutes,
42uC for 1 hour, and 70uC for 10 minutes. Samples were allowed
to cool on ice and kept at 220uC prior to use.
Western blots
To prepare protein extracts were prepared from erythrocyte
stage parasites, mice were injected with infected blood and
exsanguinated upon reaching peak parasitaemia. Collected blood
was diluted in Citrate Saline Solution and then filtered once using
a cellulose (CF11, Sigma) 5 ml column and centrifuged at
3000 rpm for 5 minutes. The pellet was washed twice in ice-cold
PBS and re-suspended into two volumes of PBS. The mixture was
divided into 500 ml aliquots. RBC lysis was performed by adding
1 ml of Hypotonic Ammonium Chloride Solution and incubating
at 4uC for 3 minutes. The samples were centrifuged at 10000 rpm
for 7 minutes at 4uC and the supernatant was discarded. The
pellet was washed twice in PBS and finally centrifuged at
10000 rpm at 4uC for 7 minutes. Pellet volume was estimated
and re-suspended into twice the volume of Loading Buffer.
Samples were kept at 220uC, and prepared as follows upon usage:
protein amounts were determined by Bradford assay (BioRadTM,
Germany). Samples were then run on NuPAGE Novex Tris-
Acetate gels (Invitrogen, Germany) and transferred onto a 0.2 mm
PDVF membrane (BioRadTM, Germany). Membranes were
blocked overnight at 4uC using 5% milk in PBS. Primary
antibodies (a-Pgh-1 and a-tubulin, diluted 1:1,000 and 1:2,000,
respectively) were incubated for 1 h at room temperature in 1%
BSA+PBS. Membranes were washed three times using PBS+0.1%
Tween for 10 min at room temperature and then blocked again in
5% milk in PBS for 1 h. Secondary antibodies (Alexa Fluor 680
goat anti-rabbit IgG, or Alexa Fluor goat anti-mouse IgG, both
diluted 1:10,000) were added to 1% BSA/PBS for 30 min at room
temperature. After washing four times in PBS +0.1% Tween for
5 min, signals were read using an Odyssey-Li-cor infrared imaging
system (Li-cor Biosciences). Fluorescence intensities for MDR1 (a -
Pgh-1) were normalized using fluorescence intensities measured
for a -tubulin. The resulting values were then expressed in relation
to AS-3CQ or AS-ATN.
The results were then expressed as means of five replicates and a
Student’s t-test was used to determine statistical significance of
results obtained.
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